BIOV Share Price Performance
Recent BIOV News & Updates
No updates
BioVersys AG Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.21
- Gross Margin
- 100.00%
- Net Profit Margin
- -1,543.20%
- Debt/Equity Ratio
- 155.5%
BioVersys AG Competitors
About BIOV
- Founded
- 2008
- Employees
- 27
- CEO
- WebsiteView website
BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patients with hepatic impairment and a bronchoalveolar lavage (BAL). The company is also developing Alpibectir that is in Phase 2a clinical trial for the treatment of pulmonary tuberculosis; BV200 to treat patients with Atopic dermatitis Staphylococcus aureus; and BV500 for non-tuberculous mycobacteria infections. It has a research and license option agreement with Shionogi & Co., Ltd. to develop novel ansamycin leads from BV500 program into clinical candidates. The company was founded in 2008 and is based in Basel, Switzerland.
Swiss Market Performance
- 7 Days: -0.2%
- 3 Months: 0.8%
- 1 Year: -1.0%
- Year to Date: 3.1%
The market has been flat in the last week, however the Consumer Staples sector is down 6.5%. As for the longer term, the market has also been flat over the past year. Looking forward, earnings are forecast to grow by 11% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading